1-Cyclohexyl-1-(4-benzyloxycyclohexyl)-2-(2-pyridinyl)ethanol-d11

1-Cyclohexyl-1-(4-benzyloxycyclohexyl)-2-(2-pyridinyl)ethanol-d11 is a deuterated form of 1-Cyclohexyl-1-(4-benzyloxycyclohexyl)-2-(2-pyridinyl)ethanol, which is a useful compound in the field of medicinal chemistry. This compound acts as a potent and selective antagonist of the G protein-coupled receptor 40 (GPR40), which is involved in glucose homeostasis and insulin secretion. Due to its pharmacological activity, it has potential therapeutic applications in the treatment of type 2 diabetes and other related metabolic disorders. The deuterated form of this compound, 1-Cyclohexyl-1-(4-benzyloxycyclohexyl)-2-(2-pyridinyl)ethanol-d11, is used in pharmacokinetic studies to determine the metabolic fate of the parent compound and to evaluate the bioavailability, distribution, and elimination of the drug in vivo. Deuterium labeling is a commonly used technique in drug development to improve the sensitivity and specificity of analytical methods such as liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy. Chemically, this compound is a chiral molecule with a molecular formula of C23H29D11NO2 and a molecular weight of 385.58 g/mol. It contains one deuterium atom in the hydroxyl group of the ethyl chain, which can be distinguished from the non-deuterated form by mass spectrometry. The synthesis of this compound involves the use of deuterated solvents and reagents to ensure the incorporation of deuterium atoms in the desired positions. Overall, 1-Cyclohexyl-1-(4-benzyloxycyclohexyl)-2-(2-pyridinyl)ethanol-d11 is a valuable tool in drug discovery and development, providing important insights into the pharmacokinetics and pharmacodynamics of GPR40 antagonists.